Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

HistoSonics Secures $250M in Series D Funding, Accelerating Commercial Expansion of Cancer Treatment Platform

HistoSonics Secures $250M in Series D Funding, Accelerating Commercial Expansion of Cancer Treatment Platform

HistoSonics, a pioneering developer of cancer treatment technology, has successfully raised $250 million in an oversubscribed Series D financing round. This substantial investment comes just two months after a syndicate of investors acquired a majority stake in the company, valuing it at $2.5 billion. The funding will primarily support the commercial expansion of HistoSonics' innovative Edison System, a non-invasive tumor treatment platform.

NoahAI News10/20/2025
Merck Unveils $3 Billion Manufacturing Expansion in Virginia, Part of $70 Billion US Investment Plan

Merck Unveils $3 Billion Manufacturing Expansion in Virginia, Part of $70 Billion US Investment Plan

Merck & Co. has announced the construction of a new $3 billion manufacturing facility at its Elkton, Virginia campus, marking a significant expansion of its US-based operations. The investment is part of the company's broader plan to allocate more than $70 billion towards manufacturing, research and development, and capital projects across the United States.

NoahAI News10/20/2025
FarmboxRx Founder Joins HLM Investment Partners, Bringing Entrepreneurial Expertise to Healthcare Startups

FarmboxRx Founder Joins HLM Investment Partners, Bringing Entrepreneurial Expertise to Healthcare Startups

Ashley Tyrner-Dolce, the founder of FarmboxRx, has joined HLM Investment Partners as an operating partner, leveraging her experience in bootstrapping and scaling a successful healthcare startup to mentor new founders in the industry. This move comes after FarmboxRx's recent acquisition by Pyx Health for nearly $50 million, marking a significant milestone in the company's journey from a bootstrapped venture to a profitable enterprise with $55 million in annual revenue.

NoahAI News10/20/2025
European Biotechs Join Forces to Tackle Neurodegenerative Diseases

European Biotechs Join Forces to Tackle Neurodegenerative Diseases

In a significant move for the pharmaceutical industry, two European biotechnology companies have announced a collaboration aimed at revolutionizing the treatment of neurodegenerative diseases. Swiss-based Indivi and Belgian firm Clouds of Care have partnered to leverage precision medicine tools in the early phases of drug development for conditions such as Alzheimer's and Parkinson's disease.

NoahAI News10/20/2025
Innovative Softgel Approach Accelerates Clinical Timelines and Cuts Costs

Innovative Softgel Approach Accelerates Clinical Timelines and Cuts Costs

In a groundbreaking development for the pharmaceutical industry, a novel on-demand manufacturing approach using softgel technology has demonstrated significant potential to accelerate clinical timelines and reduce costs in early-stage drug development. This innovative strategy, implemented by Catalent in collaboration with a sponsor, addresses longstanding challenges in Phase I clinical trials and offers a more flexible and efficient path to bringing new therapies to patients.

NoahAI News10/20/2025
Theravance Biopharma Launches Education Campaign for Rare Disease Ahead of Phase 3 Data

Theravance Biopharma Launches Education Campaign for Rare Disease Ahead of Phase 3 Data

Theravance Biopharma has initiated a physician education campaign called "Power in the Periphery" to raise awareness about neurogenic orthostatic hypotension (nOH) associated with multiple system atrophy (MSA). This strategic move comes as the company prepares for the release of pivotal phase 3 data for its investigational drug, ampreloxetine.

NoahAI News10/20/2025
Counteracting Complacency in Multiple Myeloma: The Fight Continues

Counteracting Complacency in Multiple Myeloma: The Fight Continues

In recent years, the multiple myeloma treatment landscape has undergone a remarkable transformation, with survival rates nearly doubling and over 15 FDA-approved therapies now available. However, despite these advancements, multiple myeloma remains an incurable disease, claiming thousands of lives annually. This article examines the current state of multiple myeloma research and treatment, highlighting the challenges and opportunities that lie ahead in the quest for a cure.

NoahAI News10/20/2025
FDA Leadership Exodus Leads to Industry Gains

FDA Leadership Exodus Leads to Industry Gains

In a significant shift within the pharmaceutical landscape, several former high-ranking FDA officials have transitioned to prominent roles in the private sector. This mass migration of talent comes amidst a tumultuous period for the agency, marked by leadership changes and policy shifts under the current administration.

NoahAI News10/20/2025
Grail's Galleri Cancer Blood Test Shows Promising Results, Eyes FDA Review

Grail's Galleri Cancer Blood Test Shows Promising Results, Eyes FDA Review

Grail, a biotechnology company focused on early cancer detection, has unveiled detailed data from its Pathfinder 2 study of the Galleri cancer blood test at the European Society for Medical Oncology (ESMO) 2025 conference in Berlin. The results demonstrate significant improvements in cancer detection rates and accuracy, potentially paving the way for a paradigm shift in cancer screening protocols.

NoahAI News10/20/2025
Sophia Genetics Unveils AI-Powered 'Digital Twins' for Personalized Cancer Treatment

Sophia Genetics Unveils AI-Powered 'Digital Twins' for Personalized Cancer Treatment

Sophia Genetics, a leading medtech company, has launched an innovative artificial intelligence-driven platform that creates virtual patient replicas, potentially revolutionizing cancer treatment personalization. The "Sophia DDM Digital Twins" technology aims to assist oncologists in tailoring therapies and predicting patient outcomes with unprecedented precision.

NoahAI News10/20/2025
Exelixis' Zanzalintinib Shows Promise in Colorectal Cancer, Positioning as Potential "Franchise Molecule"

Exelixis' Zanzalintinib Shows Promise in Colorectal Cancer, Positioning as Potential "Franchise Molecule"

Exelixis has unveiled promising data for its oral tyrosine kinase inhibitor (TKI) zanzalintinib, demonstrating a significant reduction in death risk for colorectal cancer patients compared to Bayer's Stivarga. The results, presented at the European Society for Medical Oncology (ESMO) Congress in Berlin, mark a potential breakthrough in the treatment of non-microsatellite instability-high metastatic colorectal cancer.

NoahAI News10/20/2025
AstraZeneca's In-House ADC Pipeline Shows Promise at ESMO

AstraZeneca's In-House ADC Pipeline Shows Promise at ESMO

AstraZeneca has unveiled promising data for its in-house antibody-drug conjugate (ADC) pipeline at the European Society for Medical Oncology (ESMO) conference in Berlin, reinforcing the company's commitment to developing next-generation cancer therapies. The pharmaceutical giant's presentation focused on AZD5335, a folate receptor α (FRα)-targeted ADC, demonstrating encouraging efficacy in patients with platinum-resistant ovarian cancer.

NoahAI News10/19/2025
«1...353637...67»